Xoma Royalty Corporation (XOMA) Stock Price, Quote & News

Company Profile

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clin...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 204 7200

Website: www.xoma.com

Address:

2200 Powell Street, Suite 310, EmeryVille, United States

TwongStocks Sep. 12 at 1:47 PM

$HLVX NASDAQ Equity Corporate Actions Alert # 2025 - 503 Information Regarding the Tender Offer of HilleVax, Inc. (HLVX) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-503 The tender offer by $XOMA to acquire all of the outstanding common stock of HilleVax, Inc. (HLVX) is scheduled to expire one minute after 11:59 p.m. ET, on September 15, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on September 17, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on September 16, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (September 17) and will be suspended effective September 18, 2025. Tender offer: HLVX shareholders will receive $1.95 plus one non-transferable contingent value right for each share held. If you own 1000 HLVX, you will receive $1950 plus 1000 CVRs.

0 · Reply

fantastex Aug. 27 at 11:56 AM

$EPIX dont trust any paid basher here. Do your DD. Still 0.22$ or capital to distribute+ 0.06$ per CVR + buyout price to be paid for a company with still $32M cash on hand. Deal backed by $XOMA this will be valued 0.50-0.70$ next week.

0 · Reply

Sswerve Aug. 20 at 7:47 PM

$MURA Congrats to the clowns who bought this over $2 . You are the proud new owners of $XOMA another failed biotech that’s down 99% since IPO. 😂🤣🤣. Tried to warn you clowns you were falling for an Irish scam. Closed out my short last week , just had to rub it in for the dudes who were calling me low IQ and retarded🤡🤡

1 · Reply

inelegantinvest Aug. 20 at 7:28 PM

Mural Oncology’s short run comes to an end. Alkermes’ 2023 biotech spin-off is being acquired by $XOMA after failed trials and heavy cash burn. What went wrong—and what does it mean for shareholders? Full story: https://www.stockspinoffs.com/2025/08/20/xoma-to-buy-failed-mural-ending-the-short-unsuccessful-run-of-the-alkermes-spinoff/ #Spinoffs #Biotech #XOMA $ALKS $XOMA

0 · Reply

inelegantinvest Aug. 20 at 7:23 PM

0 · Reply

topstockalerts Aug. 20 at 1:44 PM

$XOMA she wants to move higher..

0 · Reply

StocktwitsNews Aug. 20 at 12:52 PM

Mural Oncology To Be Acquired By Xoma Royalty $MURA $XOMA https://stocktwits.com/news/equity/markets/mural-oncology-to-be-acquired-by-xoma-royalty/chsioLsRdhL

0 · Reply

OpenOutcrier Aug. 20 at 12:37 PM

$MURA (halted pre) 98% Premium: $XOMA Royalty Acquires Cancer Drug Developer Mural Oncology in $36.2M Strategic Deal https://ooc.bz/l/74570

0 · Reply

TwongStocks Aug. 20 at 12:32 PM

$MURA Enters Agreement to be Acquired by $XOMA https://ir.muraloncology.com/news-releases/news-release-details/mural-oncology-announces-entry-agreement-be-acquired-xra-5-corp Base amount is $2.035 per share. Shareholders may receive an additional cash amount per share of up to $0.205 per share, which would be calculated on the basis of the amount by which Mural’s Closing Net Cash on the Closing Net Cash Date exceeds its Estimated Closing Net Cash.

0 · Reply

SEVENXStheGOAT Aug. 20 at 12:31 PM

$MURA to be Acquired by XRA 5 Corp, a wholly owned subsidiary of $XOMA for between $2.035 and $2.24 in Cash per Share

0 · Reply

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 8:49 AM EDT - 25 days ago

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

Aug 13, 2025, 7:30 AM EDT - 4 weeks ago

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

Aug 5, 2025, 9:20 PM EDT - 5 weeks ago

HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

HLVX

Aug 5, 2025, 6:01 PM EDT - 5 weeks ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.

HLVX

Aug 4, 2025, 7:30 AM EDT - 5 weeks ago

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

Jul 14, 2025, 8:00 AM EDT - 2 months ago

ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction

EPIX

Jul 6, 2025, 10:15 AM EDT - 2 months ago

Collect Up To 11.5% From The Healthcare Sector

THQ

Jun 27, 2025, 7:30 AM EDT - 2 months ago

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

Jun 18, 2025, 7:30 AM EDT - 3 months ago

XOMA Royalty Declares Quarterly Preferred Stock Dividends

May 27, 2025, 8:01 AM EDT - 3 months ago

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

May 7, 2025, 7:30 AM EDT - 4 months ago

XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

Apr 14, 2025, 7:30 AM EDT - 5 months ago

XOMA Royalty Completes Sale of Kinnate Pipeline Assets

Apr 8, 2025, 7:15 AM EDT - 5 months ago

BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3

TAK

Apr 8, 2025, 12:24 AM EDT - 5 months ago

XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist

Apr 2, 2025, 7:30 AM EDT - 5 months ago

XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference

Mar 17, 2025, 4:30 PM EDT - 6 months ago

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

Feb 25, 2025, 7:00 AM EST - 7 months ago

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

LGND

Feb 24, 2025, 4:05 PM EST - 7 months ago

XOMA Royalty to Present at Investor Conferences in March

Feb 4, 2025, 7:30 AM EST - 7 months ago

XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Nov 7, 2024, 7:30 AM EST - 11 months ago

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

Oct 22, 2024, 8:00 AM EDT - 11 months ago

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

Oct 22, 2024, 8:00 AM EDT - 11 months ago

Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

TWST

Oct 15, 2024, 10:31 AM EDT - 11 months ago

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

Oct 12, 2024, 10:30 AM EDT - 1 year ago

I Am Banking On The Silver Tsunami With Big Dividends

HROW THQ

Oct 3, 2024, 3:53 PM EDT - 1 year ago

XOMA Stock Dips Amidst Biotech Sector Decline

Sep 23, 2024, 6:30 AM EDT - 1 year ago

Zevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

Sep 4, 2024, 7:30 AM EDT - 1 year ago

XOMA Royalty to Present at Upcoming Investor Conferences in September

Aug 13, 2024, 7:30 AM EDT - 1 year ago

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

Jul 19, 2024, 8:30 AM EDT - 1 year ago

My 2 Top Royalty Income Picks, Yields Up To 9.5%

KRP

Jun 29, 2024, 2:31 AM EDT - 1 year ago

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

Jun 20, 2024, 7:30 AM EDT - 1 year ago

XOMA Declares Quarterly Preferred Stock Dividends

Jun 12, 2024, 7:30 AM EDT - 1 year ago

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher

Jun 3, 2024, 7:45 PM EDT - 1 year ago

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License

May 14, 2024, 7:30 AM EDT - 1 year ago

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

May 9, 2024, 7:30 AM EDT - 1 year ago

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

$XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)$

Apr 25, 2024, 7:30 AM EDT - 1 year ago

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

ANAB PGEN

Apr 3, 2024, 9:00 AM EDT - 1 year ago

XOMA Corporation Announces Closing of Tender Offer

Mar 19, 2024, 4:05 PM EDT - 1 year ago

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

Mar 13, 2024, 11:49 AM EDT - 1 year ago

KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

Mar 8, 2024, 7:30 AM EST - 1 year ago

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

Feb 28, 2024, 7:30 AM EST - 1 year ago

XOMA to Present at Upcoming Investor Conferences in March

Feb 19, 2024, 11:03 AM EST - 1 year ago

KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

Feb 16, 2024, 8:00 AM EST - 1 year ago

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

Jan 18, 2024, 8:30 AM EST - 1 year ago

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

Jan 11, 2024, 4:05 PM EST - 1 year ago

FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

Jan 8, 2024, 7:30 AM EST - 1 year ago

XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

Jan 2, 2024, 7:30 AM EST - 1 year ago

XOMA Announces Stock Repurchase Program of up to $50 Million

Dec 19, 2023, 7:30 AM EST - 1 year ago

XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties

TwongStocks Sep. 12 at 1:47 PM

0 · Reply

fantastex Aug. 27 at 11:56 AM

0 · Reply

Sswerve Aug. 20 at 7:47 PM

1 · Reply

inelegantinvest Aug. 20 at 7:28 PM

0 · Reply

inelegantinvest Aug. 20 at 7:23 PM

0 · Reply

topstockalerts Aug. 20 at 1:44 PM

$XOMA she wants to move higher..

0 · Reply

StocktwitsNews Aug. 20 at 12:52 PM

Mural Oncology To Be Acquired By Xoma Royalty $MURA $XOMA https://stocktwits.com/news/equity/markets/mural-oncology-to-be-acquired-by-xoma-royalty/chsioLsRdhL

0 · Reply

OpenOutcrier Aug. 20 at 12:37 PM

$MURA (halted pre) 98% Premium: $XOMA Royalty Acquires Cancer Drug Developer Mural Oncology in $36.2M Strategic Deal https://ooc.bz/l/74570

0 · Reply

TwongStocks Aug. 20 at 12:32 PM

0 · Reply

SEVENXStheGOAT Aug. 20 at 12:31 PM

$MURA to be Acquired by XRA 5 Corp, a wholly owned subsidiary of $XOMA for between $2.035 and $2.24 in Cash per Share

0 · Reply

TheBioFreak Aug. 13 at 3:11 PM

$XOMA https://investors.xoma.com/news-events/press-releases/detail/481/xoma-royalty-reports-second-quarter-and-year-to-date-2025

0 · Reply

TwongStocks Aug. 6 at 9:47 PM

$TSBX $XOMA NASDAQ Equity Corporate Actions Alert # 2025 - 425 Information Regarding the Tender Offer for Turnstone Biologics Corp. (TSBX) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-425 The tender offer by XOMA Royalty Corporation (XOMA) to acquire all of the outstanding common stock of Turnstone Biologics Corp. (TSBX) expires one minute after 11:59 p.m. ET, on August 7, 2025, unless extended or terminated. If successful, the subsequent merger is tentatively scheduled to close prior to the market open on August 11, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on August 8, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (August 11th) and will be suspended effective August 12, 2025. Tender offer: TSBX shareholders will receive $.34 and one (1) non-transferable Contingent Value Right (CVR) for each share held.

1 · Reply

Tycho11261 Aug. 5 at 11:48 PM

$VXRT $XOMA our only real noro competitor🔥🔥🔥 Shit's about to move, ya'll!

0 · Reply

TrendSetter67 Aug. 5 at 9:53 PM

$VXRT In case it was missed...$XOMA acquires Hillevax

1 · Reply

TwongStocks Aug. 4 at 12:53 PM

Busy weekend for $XOMA. Closed on two acquisitions. 1) Acquiring $HLVX for $1.95 per share, plus a CVR. CVR payouts as follows: • If HLVX clsoing cash is over $102.95m, CVR holders will receive a pro-rata portion of the remaining cash above that. • 90-100% of any savings from closing of HLVX's Boston office lease obligations. • 90% of any proceeds XOMA receives in the next 5 yearw from the sale or licensing of HLVX's norovirus vaccine program. Sale or license must occur within the next two years. Tender offer expected to close in Sept 2025. 2) Acquiring $LVTX for between $1.16 and $1.24 Per Share in Cash, plus CVR. CVR payout as follows: • 75% of the net proceeds related to LAVA’s two partnered assets • 75% of any net proceeds from any out license or sale of LAVA’s unpartnered programs. Tender offer expected to close in Q4 2025.

0 · Reply

OpenOutcrier Aug. 4 at 12:11 PM

$LVTY (+5.6% pre) $XOMA Royalty to acquire LAVA Therapeutics for up to $1.24 per share https://ooc.bz/l/72368

0 · Reply

OpenOutcrier Aug. 4 at 12:10 PM

$HLVX (+2.9% pre) $XOMA Royalty to acquire HilleVax for $1.95 per share plus contingent rights https://ooc.bz/l/72366

0 · Reply

NVDAMillionaire Jul. 29 at 6:16 PM

$XOMA Outstanding article that hits the mark on XOMA's current state. So if you want to refresh your XOMA insights or learn about XOMA from scratch, this is a must read. https://beyondspx.com/article/xoma-royalty-building-a-cash-flow-engine-through-strategic-aggregation-nasdaq-xoma

0 · Reply

OpenOutcrier Jul. 14 at 12:38 PM

$EPIX (+9.9% pre) $XOMA (+10.5% pre) ESSA Pharma to be acquired by XenoTherapeutics in all-cash deal https://ooc.bz/l/69826

0 · Reply

TheBioFreak Jun. 30 at 7:56 PM

$XOMA Xoma up and down as usual. 104 $ by HCW in 100 years maybe. Low float Stock…..

0 · Reply

TheBioFreak Jun. 30 at 10:12 AM

$XOMA https://www.ainvest.com/news/calculated-gamble-royalty-aggregation-xoma-turnstone-acquisition-blueprint-biotech-creation-2506/

0 · Reply

Stmkr Jun. 28 at 5:41 AM

$TSBX $XOMA I dont get it. What does XOMA get from this acquisition??

1 · Reply

Market Cap	452.33M
Revenue (ttm)	28.49M
Net Income (ttm)	-13.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	42.86
Profit Margin	-48.51%
Debt to Equity Ratio	1.57

Volume	28,600
Avg Vol	47,458
Day's Range	N/A - N/A
Shares Out	12.09M
Stochastic %K	90%
Beta	0.99
Analysts	Strong Sell
Price Target	$69.67